RCS-21
Acute exacerbations in Idiopathic Pulmonary Fibrosis (IPF)
Phase 1Active
Key Facts
Indication
Acute exacerbations in Idiopathic Pulmonary Fibrosis (IPF)
Phase
Phase 1
Status
Active
Company
About Rnatics
RNATICS is a private, preclinical-stage biotech leveraging a unique macrophage-targeting platform to develop inhaled RNA therapeutics for hard-to-treat diseases. Its lead candidate, RCS-21, is in a first-in-human study for acute exacerbations in Idiopathic Pulmonary Fibrosis (IPF), supported by a €2.7 million grant from the German Federal Ministry of Research. The company combines deep expertise in RNA biology, pulmonary medicine, and oligonucleotide chemistry to pioneer a new delivery pathway with potential applications across multiple organ systems.
View full company profile